Business & FinanceBreaking NewsBreakingLatest News
CDSCO Orders Sun Pharma to Halt Eye-Care Drug Production Over Quality Lapses
Sentiment: NeutralHigh Priority
What Happened?
Indian regulators have ordered Sun Pharmaceutical Industries to stop manufacturing ophthalmic products at its Assam facility due to quality management failures. This follows a voluntary recall of 11 eye-care brands earlier this year.
Key points
- The halt was ordered after a joint inspection revealed lapses in quality management.
- Sun Pharma had previously recalled 332 batches of ophthalmic suspension products.
- The Assam facility was expected to be a major hub for sterile products.
- Ophthalmology contributes about 3% of Sun Pharma's domestic revenue.
- The company reported a drop in second-quarter profit due to a one-time charge.
Key insights
- The regulatory action highlights ongoing concerns about drug quality in India.
- Sun Pharma's reputation may be affected by repeated quality control issues.
- The halt in production could lead to shortages of eye-care medications.
Why it matters
This action could impact the availability of essential eye-care products in the market.
Entities
Sun Pharmaceutical Industries· CompanyCentral Drugs Standard Control Organisation· OrganizationAssam· State
Source
Business Standard
